HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.

Abstract
This study evaluated the efficacy and tolerability of new extended-release (ER) tolterodine for the treatment of overactive bladder in women. In this subpopulation analysis of a double-blind multicenter trial, 1235 female patients were randomized to oral therapy with tolterodine ER 4 mg once daily (n=417), tolterodine IR 2 mg twice daily (n=408) or placebo (n=410) for 12 weeks. Both formulations reduced the mean number of urge incontinence episodes per week (both P=0.001 vs placebo); tolterodine ER was more effective than tolterodine IR (P=0.036). Both formulations significantly improved all other micturition chart variables compared to placebo. Dry mouth was the most common adverse event. There were no safety concerns. Toltrodine ER 4 mg once daily is effective and well tolerated in the treatment of women with overactive bladder, and reduces urge incontinence episodes more than the existing IR twice-daily formulation.
AuthorsS Swift, A Garely, T Dimpfl, C Payne, Tolterodine Study Group
JournalInternational urogynecology journal and pelvic floor dysfunction (Int Urogynecol J Pelvic Floor Dysfunct) Vol. 14 Issue 1 Pg. 50-4; discussion 54-5 (Feb 2003) England
PMID12601517 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzhydryl Compounds
  • Cresols
  • Delayed-Action Preparations
  • Muscarinic Antagonists
  • Phenylpropanolamine
  • Tolterodine Tartrate
Topics
  • Benzhydryl Compounds (administration & dosage, therapeutic use)
  • Cresols (administration & dosage, therapeutic use)
  • Delayed-Action Preparations
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Middle Aged
  • Muscarinic Antagonists (administration & dosage, therapeutic use)
  • Phenylpropanolamine
  • Tolterodine Tartrate
  • Urinary Bladder Diseases (drug therapy)
  • Urinary Incontinence (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: